The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy
- PMID: 20001209
- PMCID: PMC3043547
- DOI: 10.1517/14728220903431069
The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy
Abstract
Importance of the field: Nuclear factor kappa B (NF-kappaB) is activated by a variety of cancer-promoting agents. The reciprocal activation between NF-kappaB and inflammatory cytokines makes NF-kappaB important for inflammation-associated cancer development. Both the constitutive and anticancer therapeutic-induced NF-kappaB activation blunts the anticancer activities of the therapy. Elucidating the roles of NF-kappaB in cancer facilitates developing approaches for cancer prevention and therapy.
Areas covered in this review: By searching PubMed, we summarize the progress of studies on NF-kappaB in carcinogenesis and cancer cells' drug resistance in recent 10 years.
What the reader will gain: The mechanisms by which NF-kappaB activation pathways are activated; the roles and mechanisms of NF-kappaB in cell survival and proliferation, and in carcinogenesis and cancer cells' response to therapy; recent development of NF-kappaB-modulating means and their application in cancer prevention and therapy.
Take home message: NF-kappaB is involved in cancer development, modulating NF-kappaB activation pathways has important implications in cancer prevention and therapy. Due to the complexity of NF-kappaB roles in different cancers, careful evaluation of NF-kappaB's in each cancer type is crucial in this regard. More cancer cell-specific NF-kappaB inhibiting means are desired for improving anticancer efficacy and reducing systemic toxicity.
Figures

Similar articles
-
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target.Front Biosci (Landmark Ed). 2011 Jan 1;16(3):1172-85. doi: 10.2741/3782. Front Biosci (Landmark Ed). 2011. PMID: 21196225 Free PMC article. Review.
-
Nuclear factor-kappa B and cancer: its role in prevention and therapy.Biochem Pharmacol. 2002 Sep;64(5-6):883-8. doi: 10.1016/s0006-2952(02)01154-1. Biochem Pharmacol. 2002. PMID: 12213582 Review.
-
NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review).Int J Oncol. 2006 Jul;29(1):185-92. Int J Oncol. 2006. PMID: 16773199 Review.
-
NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates.Anticancer Agents Med Chem. 2017;17(4):483-490. doi: 10.2174/1871520616666160729112854. Anticancer Agents Med Chem. 2017. PMID: 27481554 Review.
-
Targeting NF-kappaB for colorectal cancer.Expert Opin Ther Targets. 2010 Jun;14(6):593-601. doi: 10.1517/14728221003769903. Expert Opin Ther Targets. 2010. PMID: 20367537 Review.
Cited by
-
NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants.Front Pharmacol. 2020 Aug 18;11:1266. doi: 10.3389/fphar.2020.01266. eCollection 2020. Front Pharmacol. 2020. PMID: 32973507 Free PMC article.
-
The NESHIE and CP Genetics Resource (NCGR): A database of genes and variants reported in neonatal encephalopathy with suspected hypoxic ischemic encephalopathy (NESHIE) and consequential cerebral palsy (CP).Genomics. 2022 Nov;114(6):110508. doi: 10.1016/j.ygeno.2022.110508. Epub 2022 Oct 18. Genomics. 2022. PMID: 36270382 Free PMC article.
-
Amicis Omnia Sunt Communia: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.Pharmaceuticals (Basel). 2024 Jun 5;17(6):734. doi: 10.3390/ph17060734. Pharmaceuticals (Basel). 2024. PMID: 38931401 Free PMC article. Review.
-
Regulation of Human Platelet Activation and Prevention of Arterial Thrombosis in Mice by Auraptene through Inhibition of NF-κB Pathway.Int J Mol Sci. 2020 Jul 7;21(13):4810. doi: 10.3390/ijms21134810. Int J Mol Sci. 2020. PMID: 32646046 Free PMC article.
-
Effect of interleukin-1β and tumor necrosis factor α gene silencing on mouse gastric cancer cell proliferation and migration.Oncol Lett. 2016 Apr;11(4):2559-2565. doi: 10.3892/ol.2016.4253. Epub 2016 Feb 19. Oncol Lett. 2016. PMID: 27073517 Free PMC article.
References
-
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. - PubMed
-
- Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18(18):2195–224. - PubMed
-
- Devin A, Cook A, Lin Y, et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000;12(4):419–29. - PubMed
-
- Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol. 2001;2(7):620–4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials